In an unprecedented global effort to end progressive MS, the International Progressive MS Alliance (Alliance) has awarded three Collaborative Network Award grants for a total investment of A$18.92 million (€12.6 million) toward accelerating the pace of progressive MS research. More than 2.8 million people worldwide live with MS and more than one million of those living with the disease have progressive MS.
The Collaborative Network Awards are multi-year grants that invest significant funding to fuel international networks of researchers and institutions that have worked together and demonstrated that their Network has potential to make crucial breakthroughs in understanding and treating progressive MS.
The 3 projects that have received Collaborative Network Awardswill focus on key priorities in quickly finding answers in relation to treating progressive MS:
Dr Douglas Arnold, from McGill University, Canada will lead 16 global investigators to identify a biomarker of disability progression for use in clinical trials. This study has the extraordinary potential to inform proactive treatment for people with not-yet-evident progressive MS and make clinical trials of new medications for progressive MS faster and more powerful.
Professor Gianvito Martino from San Raffaele Hospital Milan, Italy will work with 13 global investigators to develop an in vitro (test-tube based) platform to discover new drugs to target myelin repair and nerve protection for progressive MS, with the aim to implement a clinical trial by 2020.
Dr Francisco Quintana from Brigham and Women’s Hospital, United States will collaborate with 8 global investigators to identify drug candidates that may be effective therapies to target the innate immune system in progressive MS.
Dr Lisa Melton, Head of Research, MS Research Australia and a member of the Alliance Scientific Steering Committee said “The Alliance has implemented an extremely rigorous process to select these outstanding, and truly international, Collaborative Networks. The research they will undertake gets right to the heart of breaking down the key barriers facing us in finding answers for people with progressive forms of MS.”
The International Progressive MS Alliance is a worldwide collaborative of MS organisations including MS Research Australia that fund developments in progressive MS research, including disease-modifying therapies and symptom treatments.
“MS Research Australia is proud to be a managing member of the International Progressive MS Alliance. We have committed A$1.1million to the Alliance to help fast track the type of discoveries that can truly change lives for people with progressive MS” said Dr Matthew Miles, CEO, MS Research Australia
Up to 65% of those living with relapsing-remitting MS are at risk of developing secondary progressive MS, and 15% are diagnosed with primary progressive MS from the outset – making the need for both collaboration and acceleration of the pace of research a global priority.
Mr Jesse Frick who was diagnosed with MS when he was 18 said “being a young person, I want to do all the things that my friends are doing, like getting married, progressing my career, buying a house etc but those wants seem unattainable to me and the future that I thought I had feels out of reach. That’s why the work of the International Progressive MS Alliance is so important to me, because it could help me to have a future that isn’t dictated by severe and progressive disability.”
To date, the Alliance has committed almost A$34.6 million (€23 million) in cumulative global research investments. The Collaborative Network Awards aim to accelerate progress in:
About Progressive MS: Progressive multiple sclerosis, a chronic condition that disrupts the flow of information within the brain and body, is a form of MS that gets worse over time. Each day, progressive MS takes things away from people: vision, mobility, cognition, ability to work, and their very independence. MS is found in every country where studies have been conducted, and more than 2.8 million people worldwide currently live with the disease; over 1 million people live with a progressive form of MS.
About the International Progressive MS Alliance: Ending progressive MS is an urgent and unmet need that must be overcome so that people affected by MS can live their lives without the uncertainty of what tomorrow will bring. The International Progressive MS Alliance is an unprecedented international initiative that is connecting resources and experts around the world to find answers and develop solutions to end progressive MS. The goal of the Alliance is to speed the development of new treatments for progressive MS by funding the best research, wherever it exists. The Alliance is led with management from MS organisations in Australia, Canada, Italy, the U.K, the U.S., and the MS International Federation, and expanding financial and resource support from these and other organisations, including the MS organisations in Belgium, Denmark, France, Germany, Norway, the Netherlands, Ireland, Spain and Sweden.
In addition, the Alliance engages with the pharmaceutical and biotech industry, as they have the ability to contribute extensive knowledge, resources and financial investment. Industry’s collaborative partnership with the Alliance is managed through the Industry Forum – the framework where Alliance and industry stakeholders discuss and actively support and influence the critical work of the Alliance.
Learn more at www.ProgressiveMSAlliance.org.
Douglas Arnold, M.D., McGill University (Canada) in collaboration with 16 investigators from The Netherlands, U.K., U.S., and Switzerland.
Project Title: Identifying a biomarker of disability progression for use in clinical trials
Douglas Arnold, M.D. of McGill University is making remarkable headway in developing the next generation of tools for measuring disease progression in progressive MS. Dr. Arnold’s team is pioneering the development of magnetic resonance imaging (MRI) markers that signal disease progression, and adapting these for use in early (phase 2) clinical trials of progressive MS treatments.
Dr. Arnold’s research examines the underlying idea that brain injury-associated disease progression in MS is detectable by MRI prior to its identification by physicians in a clinic visit, likely due to the ability of the brain to compensate for injury, up to a point. The innovative tools being developed by Dr. Arnold and his team are essential for planning the larger scale phase 3 clinical trials required for approval of new treatments. The study also has extraordinary potential to inform proactive treatment for people with not-yet-evident progressive MS.
Gianvito Martino, M.D., Division of Neuroscience, San Raffaele Hospital Milan (Italy) in collaboration with 13 Investigators from Italy, France, Germany, Europe, Canada and the U.S.
Project Title: Bioinformatics and cell reprogramming to develop an in vitro platform to discover new drugs for progressive multiple sclerosis (BRAVEinMS)
The BRAVEinMS team is working to identify molecules that may have a protective role in nerve cells or neurons and/or the capacity to promote myelin repair. They will focus their efforts in three phases – i) identifying potential drugs or compounds using sophisticated bioinformatics tools specifically developed to virtually reproduce pathogenic mechanisms of MS; ii) screening these compounds for their ability to protect nerve cells or promote myelin repair in laboratory tests using both rodent and human neurons and myelin forming cells; and iii) evaluating in animal models of progressive MS the therapeutic potential of the ‘candidate’ compounds identified through the in vitro screening.
The research team believes that BRAVEinMS will pinpoint a limited number of previously unidentified molecules with a high chance of therapeutic power in progressive MS patients. They expect that within four years from the start of the project they will identity one or two human grade compounds that can be used in Phase I/II clinical trials in patients with progressive MS. As a result, the team aims to implement a clinical trial in the near future, by the end of 2020.
Francisco Quintana, Ph.D., Brigham and Women’s Hospital (U.S) in collaboration with 8 Investigators from the U.S., Canada, Israel and Sanofi Genzyme
Project Title: Development of a drug discovery pipeline for progressive MS
The goal of Francisco Quintana, Ph.D.’s project is to identify drug candidates that may be effective therapies for progressive MS, and that will be ready for evaluation in patients within four years of the initiation of this research. The project’s central idea is that targeting the innate immune system in the central nervous system will uncover effective therapeutic approaches for progressive MS. The innate immune system normally functions to protect the body from infections. Dr. Quintana and others have found that innate immune cells in the central nervous system promote disease activity in MS and other diseases. Dr. Quintana’s team recently identified the biological pathways that control the innate immune response. They also found that genetic manipulation of the pathways can arrest nerve damage and alter disease progression in pre-clinical MS animal models; however no candidate drugs are available to modulate the activity of innate immune cells.
Dr. Quintana’s study will: i. Identify the biological processes that control the innate immune response in the central nervous system; ii. Evaluate the activity of candidate drugs on the innate immune system in experimental models of progressive MS; iii. Analyze how the candidate drugs exert their beneficial effect; and, iv. Identify additional candidate targets and therapeutic drugs that impact the innate immune system in progressive MS.